An independent two-stage DCF analysis by a frontier AI model.
McKesson Corporation is an essential pillar of the North American healthcare infrastructure. By delivering a third of all pharmaceutical products used in the region, it operates as a massive, highly efficient toll road that generates over $9.1B in predictable free cash flow. The company's strategic pivot toward higher-margin specialty distribution and health information technology is successfully offsetting the structural low margins (1.5% operating margin) of its core wholesale business.
Our valuation highlights McKesson's tremendous cash-generating ability. The combination of steady 11.4% top-line growth, disciplined cost management, and a relentless focus on share repurchases creates a compelling compounding machine. The stock appears attractively valued, offering a margin of safety for long-term investors within the defensive healthcare sector.
The 6.0% growth rate assumption reflects our balanced view on the company's ability to grow free cash flow over the next 5 years.
A 8.0% discount rate is applied to reflect the risk profile and cost of capital.
The 2.0% terminal growth rate is consistent with long-term macroeconomic expectations.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $2,060.23 | $1,716.86 | $1,471.59 | $1,287.65 | $1,144.57 |
| 1.5% | $2,289.15 | $1,872.94 | $1,584.79 | $1,373.49 | $1,211.90 |
| 2.0% | $2,575.29 | $2,060.23 | $1,716.86 | $1,471.59 | $1,287.65 |
| 2.5% | $2,943.19 | $2,289.15 | $1,872.94 | $1,584.79 | $1,373.49 |
| 3.0% | $3,433.72 | $2,575.29 | $2,060.23 | $1,716.86 | $1,471.59 |
■ Undervalued vs current price ■ Overvalued vs current price
A 2.0% terminal growth rate reflects a mature, low-margin business that will grow roughly in line with long-term inflation and healthcare utilization trends.
The 8.0% discount rate accounts for the company's defensive characteristics and low beta of 0.35, while acknowledging regulatory and drug pricing risks in the healthcare sector.
The 6% growth assumption is driven by the continued expansion of specialty pharmaceuticals, operating leverage, and the positive impact of share buybacks on per-share metrics.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.